{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:14:43Z","timestamp":1777518883015,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.034","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T09:17:53Z","timestamp":1602580673000},"page":"7588-7595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry"],"prefix":"10.1016","volume":"38","author":[{"given":"L.","family":"Coudeville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.B.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Jollivet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Thommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Druelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-7057","authenticated-orcid":false,"given":"S.S.","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.034_b0005","unstructured":"World Health Organization. Pneumonia of unknown cause \u2013 China. https:\/\/www.who.int\/csr\/don\/05-january-2020-pneumonia-of-unkown-cause-china\/en\/. Last accessed 17 July 2020"},{"key":"10.1016\/j.vaccine.2020.10.034_b0010","unstructured":"John Hopkins University. Coronavirus Resource Center. https:\/\/coronavirus.jhu.edu\/map.html. Last accessed 17 July 2020"},{"key":"10.1016\/j.vaccine.2020.10.034_b0015","unstructured":"OECD. Evaluating the initial impact of COVID-19 containment measures on economic activity. https:\/\/read.oecd-ilibrary.org\/view\/?ref=126_126496-evgsi2gmqj&title=Evaluating_the_initial_impact_of_COVID-19_containment_measures_on_economic_activity (2020). Last accessed 20 June 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0020","unstructured":"National Institute of Health. ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Last accessed 20 June 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0025","unstructured":"World Health Organization. \u2018Solidarity\u2019 clinical trial for COVID-19 treatments. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2020.10.034_b0035","unstructured":"Lowe D. In the pipeline: Coronavirus Vaccine Prospects. Science Translational Medicine blog https:\/\/blogs.sciencemag.org\/pipeline\/archives\/2020\/04\/15\/coronavirus-vaccine-prospects."},{"key":"10.1016\/j.vaccine.2020.10.034_b0040","unstructured":"National Institute of Health. NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options; 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0045","unstructured":"Reuters. Moderna receives $483 million BARDA award for COVID-19 vaccine development. Reuters; 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0050","article-title":"GSK and Sanofi team up on Covid-19 vaccine","author":"Neville","year":"2020","journal-title":"Financial Times"},{"key":"10.1016\/j.vaccine.2020.10.034_b0055","unstructured":"World Health Organization. WHO global influenza preparedness plan\u00a0: the role of WHO and recommendations for national measures before and during pandemics. https:\/\/apps.who.int\/iris\/handle\/10665\/68998; 2005."},{"key":"10.1016\/j.vaccine.2020.10.034_b0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41577-020-00451-5","article-title":"COVID-19 herd immunity: where are we?","volume":"20","author":"Fontanet","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.10.034_b0065","unstructured":"Imperial College London. Percentage of total population infected. https:\/\/mrc-ide.github.io\/covid19estimates\/#\/total-infected."},{"key":"10.1016\/j.vaccine.2020.10.034_b0070","article-title":"Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland","author":"Stringhini","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2020.10.034_b0075","doi-asserted-by":"crossref","unstructured":"Buss LF, et al. COVID-19 herd immunity in the Brazilian Amazon, preprint, medRxiv 2020.09.16.20194787; doi: https:\/\/doi.org\/10.1101\/2020.09.16.20194787.","DOI":"10.1101\/2020.09.16.20194787"},{"key":"10.1016\/j.vaccine.2020.10.034_b0080","unstructured":"Banaji M. What Do the Delhi and Mumbai Sero-Survey Results Tell Us About COVID-19 in India? The Wire, July 31st 2020, 33,34, last accessed 24 September 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/318323a0","article-title":"Vaccination and herd immunity to infectious diseases","volume":"318","author":"Anderson","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.10.034_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","article-title":"T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV","volume":"137","author":"Liu","year":"2017","journal-title":"Antiviral Res."},{"issue":"792\u2013795","key":"10.1016\/j.vaccine.2020.10.034_b0095","first-page":"14","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"Liu","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2020.10.034_b0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.vaccine.2020.10.034_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S0022172400062410","article-title":"Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection","volume":"95","author":"Callow","year":"1985","journal-title":"J. Hyg. (Lond.)"},{"key":"10.1016\/j.vaccine.2020.10.034_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa161","article-title":"Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan","author":"Monto","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2020.10.034_b0115","first-page":"eabb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","author":"Kissler","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.10.034_b0120","unstructured":"Snyder et al Health Affairs, July 2020 https:\/\/www.healthaffairs.org\/doi\/full\/10.1377\/hlthaff.2020.00646."},{"key":"10.1016\/j.vaccine.2020.10.034_b0125","unstructured":"U.S. Department of Health & Human Services. Fact Sheet: Explaining Operation Warp Speed. https:\/\/www.hhs.gov\/about\/news\/2020\/06\/16\/fact-sheet-explaining-operation-warp-speed.html. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0130","unstructured":"European Commission. Coronavirus: Commission unveils EU vaccines strategy. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_20_1103. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0135","unstructured":"World Health Organization. The Access to COVID-19 Tools (ACT) Accelerator. https:\/\/www.who.int\/initiatives\/act-accelerator. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-020-0204-7","article-title":"Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens","volume":"5","author":"Wolf","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.10.034_b0145","unstructured":"Integrating clinical research into epidemic response: the Ebola experience. (The National Academies Press, 2017)."},{"key":"10.1016\/j.vaccine.2020.10.034_b0150","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-virology-013120-013123","article-title":"Ethics of conducting clinical research in an outbreak setting","author":"Edwards","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.vaccine.2020.10.034_b0155","article-title":"Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries","author":"Murray","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2020.10.034_b0160","unstructured":"US CDC. Mathematical modeling: Forecasts of Total Deaths. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/forecasting-us.html. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0165","unstructured":"US CDC. COVID-19 Pandemic Planning Scenarios. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/planning-scenarios.html. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0170","unstructured":"ECDC. COVID-19. https:\/\/qap.ecdc.europa.eu\/public\/extensions\/COVID-19\/COVID-19.html. Last accessed 17 July 2020."},{"key":"10.1016\/j.vaccine.2020.10.034_b0175","article-title":"Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2","author":"Korber","year":"2020","journal-title":"bioRxiv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:54Z","timestamp":1759402134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313281"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}